Sfoglia per AUTORE
MARASCA R
Collezione AOU San Luigi di Orbassano

  

Items : 2

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...

VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: Results from a cohort analysis of a phase III randomized controlled trial in Haematologica

2011
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Morabito F; Gentile M; Mazzone C; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci M; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Musto P; Liberati A; Cascavilla N; Cangialosi C; Majolino I; Musolino C; Zambello R; Di Raimondo F; Cavo M; Boccadoro M; Palumbo A;